Halaven Injection
Product Images NDC 62856-389
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Halaven (NDC 62856-389). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Eisai Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1: Updated Overall Survival Analysis For Study 1 (Halaven 02)
Kaplan-meier Curves Of Overall Survival In The Liposarcoma Stratum In Study 2 (Halaven 03)
Ndc 62856-389-01halaven™(eribulin Mesylate) Injection1 mg/2 mL(0.5 mg/ml)for Intravenous Use (Halaven 04)
Halaven 05
Halaven (eribulin mesylate) Injection is a sterile solution that is distributed by Esa n. It is made in Japan and is for intravenous use only. It must be stored at room temperature and should not be frozen or refrigerated. The dosage and use should be determined by accompanying prescribing information, and caution should be taken as it is a cytotoxic agent. The product comes in a single-dose vial, and any unused portions should be discarded. Lot number is 2005365.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.